Prestige Biopharma has been frustrated in its efforts to win a European approval for its HD201 biosimilar rival to Herceptin (trastuzumab), after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued negative opinions recommending the refusal of marketing authorization applications submitted for the product under the Tuznue and Hervelous labels.
While Prestige did not immediately respond to Generics Bulletin enquiries over the next steps for the application, the CHMP noted...






